MarketCap
Facebook
X
Telegram
Kala Pharmaceuticals Balance Sheet 2025-2011 | KALA
Brief overview of Kala Pharmaceuticals's financial position
The comparison uses five available annual reports from the 2021–2025 interval.
Assets finished at $9.5 million versus $139.4 million initially, losing -93.2%. The balance sheet contracted.
The growth rates were balanced: assets changed -93.2%, while liabilities changed -98%.
The equity-to-assets ratio is 73.7%, compared with 12.1% five periods ago. The balance sheet has a substantial internal cushion.
The cash reserve occupies 79.6% of the balance sheet, previously 66.1%. It is one marker of short-term resilience.
Retained earnings remain negative at -$694.9 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
Kala Pharmaceuticals's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Kala Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -30.7 M | -16.4 M | -32.5 M | -12.5 M | 1.65 M | 15.7 M | -71.5 M | -95.9 M | -35.8 M | 4.04 M | - | - | - | - |
Long Term Debt |
- | 20.1 M | 34.2 M | 37.9 M | 78.9 M | 72.2 M | 71.2 M | 70.2 M | 12 M | 9.1 M | 7.8 M | - | - | - | - |
Long Term Debt Current |
- | 380 K | 334 K | 13 K | 711 K | 1.53 M | 1.33 M | 463 K | 6.67 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 26.2 M | 40.1 M | 42.2 M | 85.2 M | 99.4 M | 99.9 M | 99 M | 12 M | 129 M | 59.6 M | - | - | - | - |
Total Current Liabilities |
2.49 M | 17 M | 8.35 M | 25.7 M | 37.4 M | 22.2 M | 24.8 M | 17 M | 14.5 M | - | - | - | - | - | - |
Total Liabilities |
2.49 M | 43.2 M | 48.4 M | 67.8 M | 123 M | 122 M | 125 M | 116 M | 26.5 M | 134 M | 65.1 M | - | - | - | - |
Deferred Revenue |
- | - | - | 4.19 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-695 M | -668 M | -629 M | -587 M | -542 M | -400 M | -295 M | -201 M | -134 M | -92.1 M | -59 M | - | - | - | - |
Total Assets |
9.49 M | 55.5 M | 55.9 M | 86.8 M | 139 M | 222 M | 154 M | 221 M | 116 M | 46.3 M | 8.45 M | - | - | - | - |
Cash and Cash Equivalents |
7.56 M | 51.2 M | 50.9 M | 70.5 M | 92.1 M | 77.3 M | 85.4 M | 171 M | 115 M | 45.6 M | - | - | - | - | - |
Book Value |
7 M | 12.3 M | 7.5 M | 19 M | 16.8 M | 100 M | 29.7 M | 105 M | 89.7 M | -87.8 M | -56.7 M | - | - | - | - |
Total Shareholders Equity |
7 M | 12.3 M | 7.5 M | 19 M | 16.8 M | 100 M | 29.7 M | 105 M | 89.7 M | -87.8 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Kala Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 1.43 M | 26.9 M | 18.8 M | 15.1 M | 20.1 M | 17.2 M | 22.8 M | 28.5 M | 34.2 M | 33.9 M | 33.6 M | 3.08 M | 37.9 M | 42.6 M | 79.8 M | 79.4 M | 78.9 M | 78.5 M | 78.1 M | 72.5 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 71.2 M | 71.2 M | 71.2 M | 71.2 M | 70.2 M | 70.2 M | 70.2 M | 70.2 M | 12 M | 12 M | 12 M | 12 M | 9.1 M | 9.1 M | 9.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 26.2 M | 1.11 M | 23.2 M | 19.6 M | 26.2 M | 23.4 M | 28.7 M | 34.5 M | 40.1 M | 39.6 M | 39.2 M | 38.5 M | 42.2 M | 46.4 M | 83.6 M | 84.1 M | 85.2 M | 105 M | 105 M | 100 M | 99.4 M | 99.4 M | 99.4 M | 99.4 M | 99.9 M | 99.9 M | 99.9 M | 99.9 M | 99 M | 99 M | 99 M | 99 M | 12 M | 12 M | 12 M | 12 M | 10.2 M | 10.2 M | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.49 M | 1.56 M | 43.2 M | 33.7 M | 39.3 M | 42.5 M | 43.2 M | 47.2 M | 47.9 M | 46.4 M | 48.4 M | 49.9 M | 49 M | 48.8 M | 67.8 M | 86.7 M | 117 M | 117 M | 123 M | 132 M | 131 M | 120 M | 122 M | 122 M | 122 M | 122 M | 125 M | 125 M | 125 M | 125 M | 116 M | 116 M | 116 M | 116 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M | 15.7 M | 15.7 M | 15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 4.19 M | 4.19 M | 4.19 M | 3.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-695 M | -697 M | -668 M | -696 M | -688 M | -677 M | -668 M | -660 M | -651 M | -641 M | -629 M | -621 M | -612 M | -602 M | -587 M | -574 M | -603 M | -575 M | -542 M | -495 M | -467 M | -430 M | -400 M | -400 M | -400 M | -400 M | -295 M | -295 M | -295 M | -295 M | -201 M | -201 M | -201 M | -201 M | -134 M | -134 M | -134 M | -134 M | -92.1 M | -92.1 M | -92.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
9.49 M | 12.3 M | 55.5 M | 25 M | 36.1 M | 48.3 M | 55.5 M | 54.1 M | 61.6 M | 53 M | 55.9 M | 61.1 M | 66.5 M | 72.2 M | 86.8 M | 85.7 M | 85 M | 112 M | 139 M | 194 M | 215 M | 230 M | 222 M | 222 M | 222 M | 222 M | 154 M | 154 M | 154 M | 154 M | 221 M | 221 M | 221 M | 221 M | 117 M | 117 M | 117 M | 117 M | 46.3 M | 46.3 M | 46.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
7.56 M | 1.76 M | 51.2 M | 21.1 M | 31.9 M | 42.2 M | 51.2 M | 49.2 M | 54.2 M | 48.5 M | 50.9 M | 56.1 M | 49.3 M | 63.6 M | 70.5 M | 52.4 M | 42.6 M | 65.2 M | 92.1 M | 125 M | 145 M | 128 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 85.4 M | 85.4 M | 85.4 M | 139 M | 171 M | 171 M | 171 M | 171 M | 115 M | 122 M | 26.4 M | 115 M | 45.5 M | 51.9 M | 45.5 M | - | 5.76 M | - | - | - | 10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
7 M | 10.8 M | 12.3 M | -8.66 M | -3.21 M | 5.71 M | 12.3 M | 6.86 M | 13.7 M | 6.66 M | 7.5 M | 11.2 M | 17.5 M | 23.5 M | 19 M | -968 K | -31.6 M | -5.28 M | 16.8 M | 61.5 M | 84.3 M | 110 M | 100 M | 100 M | 100 M | 100 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 105 M | 105 M | 105 M | 105 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | 30.6 M | 30.6 M | 30.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
12.3 M | 10.8 M | 7.5 M | -8.66 M | -3.21 M | 5.71 M | 12.3 M | 6.86 M | 13.7 M | 6.66 M | 7.5 M | 11.2 M | 17.5 M | 23.5 M | 19 M | -968 K | -31.6 M | -5.28 M | 16.8 M | 61.5 M | 84.3 M | 110 M | 100 M | 100 M | 100 M | 100 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 105 M | 105 M | 105 M | 105 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | -87.8 M | -87.8 M | -87.8 M | - | -56.7 M | - | - | - | -40.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Kala Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada